Different effects of imidapril and enalapril on aminopeptidase P activity in the mouse trachea

Hypertension Research

Volumn 28, Issue 3, 2005, Pages 243-247

  Sakamoto, Koh Ichi ^a   Sugimoto, Koh Ichi ^a   Sudoh, Toshiaki ^a   Fujimura, Akio ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Aminopeptidase P; Bradykinin; Dry cough; Enalapril; Imidapril

Indexed keywords

AMINOPEPTIDASE P; BRADYKININ; ENALAPRIL; ENALAPRILAT; IMIDAPRIL; IMIDAPRILAT;

AIRWAY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; COUGHING; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG DETERMINATION; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG INHIBITION; DRUG MECHANISM; ENZYME ACTIVITY; IN VITRO STUDY; IN VIVO STUDY; LUNG; MALE; MOUSE; NONHUMAN; TRACHEA;

AMINOPEPTIDASES; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BRADYKININ; COUGH; ENALAPRIL; ENZYME ACTIVATION; IMIDAZOLIDINES; MALE; MICE; MICE, INBRED ICR; TRACHEA;

EID: 20444496071     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.28.243     Document Type: Article

References (20)

1. Jackson EK, Garrison JC: Renin and angiotensin, in Hardman JG, Limbird LE (eds): Goodman & Gilman's the Pharmacological Basis of Therapeutics. 9th ed. New York, McGraw-Hill, 1996, pp 733-758.
2. Fox AJ, Lalloo UG, Belvisi MG, Bernareggi M, Chung KF, Barnes PJ: Bradykinin-evoked sensitization of airway sensory nerves: a mechanism for ACE-inhibitor cough. Nat Med 1996; 2: 814-817.
3. Saruta T, Omae T, Kuramochi M, et al: Imidapril hydrochloride in essential hypertension: a double-blind comparative study using enalapril maleate as a control. J Hypertens 1995; 13 (Suppl 3): S23-S30.
4. Saruta T, Arakawa K, Iimura O, et al: Difference in the incidence of cough induced by angiotensin converting enzyme inhibitors: a comparative study using imidapril hydrochloride and enalapril maleate. Hypertens Res 1999; 22: 197-202.
5. Linz W, Wiemer G, Gohlke P, Unger T, Schölkens BA: Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995; 47: 25-49.
6. Sakamoto K, Sugimoto K, Fujimura A: Different potentiating effects of imidapril and enalapril on kaolin-induced writhing reaction in mice. Life Sci 2001; 68: 2415-2421.
7. Sakamoto K, Sugimoto K, Fujimura A: Different inhibition of enalaprilat and imidaprilat on bradykinin metabolizing enzymes. Life Sci 2000; 67: 2159-2165.
8. Kasahara Y, Ashihara Y: Colorimetry of angiotensin-converting enzyme activity in serum. Clin Chem 1981; 27: 1922-1925.
9. Holtzman EJ, Pillay G, Rosenthal T, Yaron A: Aminopeptidase P activity in rat organs and human serum. Anal Biochem 1987; 162: 476-484.
10. Mabuchi M, Kano Y, Fukuyama T, Kondo T: Determination of imidapril and imidaprilat in human plasma by high-performance liquid chromatography-electrospray ionization tandem mass spectrometry. J Chromatogr 1999; 734: 145-153.
11. Squire IB, O'kane KPJ, Anderson N, Reid JL: Bradykinin B2 receptor antagonism attenuates blood pressure response to acute angiotensin-converting enzyme inhibition in normal men. Hypertension 2000; 36: 132-136.
12. Zee RYL, Rao VS, Paster RZ, Sweet CS, Lindpaintner K: Three candidate genes and angiotensin-converting enzyme inhibitor-related cough. Hypertension 1998; 31: 925-928.
13. Mukae S, Aoki S, Itoh S, Twata T, Ueda H, Katagiri T: Bradykinin B2 receptor gene polymorphism is associated with angiotensin-converting enzyme inhibitor-related cough. Hypertension 2000; 36: 127-131.
14. Sumino H, Ichikawa S, Ohyama Y, et al: Effect of hormone replacement therapy on serum angiotensin-converting enzyme activity and plasma bradykinin in postmenopausal women according to angiotensin-converting enzyme-genotype. Hypertens Res 2003; 26: 53-58.
15. Murata T, Matsumoto Y, Kashida T, et al: Difference among angiotensin-converting enzyme inhibitors in potentiating effects on bradykinin-induced airway microvascular leakage in guinea pig airways. Jpn J Pharmacol 1995; 69: 111-118.
16. Damas J, Liégeois J-F, Simmons WH: Potentiation of the pro-inflammatory effects of bradykinin by inhibition of angiotensin-converting enzyme and aminopeptidase P in rat paws. Naunyn-Schmiederbergs Arch Pharmacol 1996; 354: 670-676.
17. Kim K-S, Kumar S, Simmons WH, Brown NJ: Inhibition of aminopeptidase P potentiates wheal response to bradykinin in angiotensin-converting enzyme inhibitor-treated humans. J Pharmacol Exp Ther 2000; 292: 295-298.
18. Emanueli C, Grady EF, Madeddu P, et al: Acute ACE inhibition causes plasma extravasation in mice that is mediated by bradykinin and substance P. Hypertension 1998; 31: 1299-1304.
19. Morice AH, Brown MJ, Higenbottam T: Cough associated with angiotensin converting enzyme inhibition. J Cardiovasc Pharmacol 1989; 13 (Suppl 3): S59-S62.
20. Regoli D, Barabe J: Pharmacology of bradykinin and related peptides. Pharmacol Rev 1980; 32: 1-46.